Prosecution Insights
Last updated: April 19, 2026
Application No. 18/212,744

Systems and Methods for Sinus Access

Non-Final OA §102§103§DP
Filed
Jun 22, 2023
Examiner
WILLIAMS, CATHERINE SERKE
Art Unit
3993
Tech Center
3900
Assignee
Intersect Ent International GmbH
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
93%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allow Rate
77 granted / 116 resolved
+6.4% vs TC avg
Strong +26% interview lift
Without
With
+26.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
26 currently pending
Career history
142
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
34.2%
-5.8% vs TC avg
§102
18.6%
-21.4% vs TC avg
§112
25.2%
-14.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 116 resolved cases

Office Action

§102 §103 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Data Sheet The ADS should be updated to indicate that the previous application (18/877,146) has been abandoned. A request for corrected filing sheet should also be filed. Drawings The drawings are objected to under 37 CFR 1.83(a) because they fail to show the interaction of the bump 1516 with the interior of the shell walls 1512 in order to provide haptic feedback as described in the specification. Specifically, Fig 15A shows the bump 1516 within the syringe barrel 1504. However, this configuration is not in any way structured to interact with the shell walls 1512. Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d). The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the “mechanism for providing a click to indicate to a user to stop depressing the plunger” (claim 26) must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 24 is objected to because of the following informalities: the claim states that the syringe barrel includes a window; however, both the drawings and the specification refer to the window 1410 being in the shell housing 1408. Appropriate correction is required. Claims 27-28 are objected to because of the following informalities: these claims are duplicate claims. Appropriate correction is required. Claims 27-28 objected to because of the following informalities: both claims depend from claim 3 which has been cancelled. Appropriate correction is required. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 21-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4, 14 and 20-21 of U.S. Patent No. 10,688,289 (“the ‘289 patent”). Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are a patentably non-distinct subcombination of the combination claimed in the ‘289 patent. See Table 1 below. Claim Limitation The instant claims The ‘289 patent claims An inflation and deflation device comprising: 21 1; 14, 20 a housing; 21 1 (a housing would be an obvious incorporation into the claim and is recited in claim 4); 14, 20 a syringe barrel, 21 1; 14, 20 having a fluid connection port, 21 (claims fluid connection port; 1 fluid connection port is a broader recitation) 1; 14, 20 (claims second fluid connection port) the fluid connection port configured to be in fluid communication with a second fluid connection port on a second device; 21 1; 14, 20 (second fluid connection port in fluid connection with first fluid connection port of the delivery device) a plunger arranged to reversibly move a length within the syringe barrel; and 21 1; 14, 20 a locking mechanism configured to limit the length the plunger can depress within the syringe barrel. 21 1; 14, 20 wherein the locking mechanism comprises a pair of pawls configured to extend outward and physically interface with the housing 22 4; 21 wherein the second device is an applicator device comprising an expandable member. 23 1; 14 Table 1 Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 21-23 and 27-28 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US Pub. No. 2014/0074140 to Johnson et al. (“Johnson”). Regarding claim 21, Johnson discloses an inflation and deflation device comprising a housing (860,960) a syringe barrel (880,990) having a fluid connection port (884,984), the fluid connection port configured to be in fluid communication with a second fluid connection port on a second device; a plunger (900,1000) arranged to reversibly move a length within the syringe barrel, and a locking mechanism (1006,1030) configured to limit the length the plunger can depress within the syringe barrel. See the embodiment of Figs. 18-21E Regarding claim 22, Johnson discloses the device of claim 1 and further teaches wherein the locking mechanism comprises a pair of pawls (1006) configured to extend outward and physically interface with the housing (860,960) as best seen in at least FIGS. 18-21 and as set forth in paras [0139-0156]. Regarding claim 23, Johnson discloses the device of claim 1 and further teaches wherein the second device is an applicator device (10) comprising an expandable member (14). Regarding claims 27-28, Johnson discloses the device of claim 1 and further teaches wherein the device is configured to deliver fluid to expand the expandable member of the applicator device at a force of from about two to about 16 atmospheres. See para. [0077] teaching the inflation of the dilator to a range of 10-12 atmospheres. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 24 is/are rejected under 35 U.S.C. 103 as being unpatentable over Johnson. Johnson meets the claim limitations as described above for claim 21 but Johnson does not teach a window in the embodiment of Figs. 18-21E. However, Johnson discloses a window (862) in the housing (860) of the embodiment of Figs. 13-17C. At the time of filing, it would have been obvious to incorporate the housing of the embodiment of Figs. 13-17C into the embodiment of Figs. 18-21E. Having the housing extend to incorporate the syringe while still including a window to see the contents of the syringe would provide the embodiment of Figs. 18-21E with the protective outer covering of the housing and still enable visualization of the syringe contents. This would have been done in order to enhance the connection of the syringe to the locking mechanism. Regarding claims 25-26, Johnson discloses the device of claim 1 and further teaches that lock mechanism includes sawteeth (1006). The sawteeth (1006) are capable of making a clicking noise and feeling as the teeth transfer over pawl (1014). Therefore, at the time of filing it would have been obvious for one skilled in the art to construct the locking mechanism of Johnson so that the sawteeth click over the pawl in order to provide the user with a tactile sensation of increments of injection. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE SERKE WILLIAMS whose telephone number is (571)272-4970. The examiner can normally be reached Monday through Friday core hours 8am-4pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Eileen Lillis can be reached at 571-272-6928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CATHERINE S WILLIAMS/Primary Examiner, Art Unit 3993
Read full office action

Prosecution Timeline

Jun 22, 2023
Application Filed
Jan 19, 2026
Non-Final Rejection — §102, §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12569663
Connector Safety Shield
2y 5m to grant Granted Mar 10, 2026
Patent 12495878
HAIRSTYLING APPARATUSES AND RELATED METHODS
2y 5m to grant Granted Dec 16, 2025
Patent RE50549
Focused Intraluminal Lithectomy Catheter Device and Methods
2y 5m to grant Granted Aug 26, 2025
Patent RE50480
PORTABLE DRINKING DEVICE
2y 5m to grant Granted Jul 08, 2025
Patent RE50441
INJECTION DEVICE
2y 5m to grant Granted May 27, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
93%
With Interview (+26.4%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 116 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month